These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 17049201)

  • 21. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
    J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
    [TBL] [Abstract][Full Text] [Related]  

  • 22. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.
    Finckh A; Ciurea A; Brulhart L; Kyburz D; Möller B; Dehler S; Revaz S; Dudler J; Gabay C;
    Arthritis Rheum; 2007 May; 56(5):1417-23. PubMed ID: 17469098
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor necrosis factor-α blockade, cardiovascular outcomes, and survival in rheumatoid arthritis.
    Al-Aly Z; Pan H; Zeringue A; Xian H; McDonald JR; El-Achkar TM; Eisen S
    Transl Res; 2011 Jan; 157(1):10-8. PubMed ID: 21146146
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor alpha blocker therapy.
    Gonzalez-Juanatey C; Llorca J; Vazquez-Rodriguez TR; Diaz-Varela N; Garcia-Quiroga H; Gonzalez-Gay MA
    Arthritis Rheum; 2008 Dec; 59(12):1821-4. PubMed ID: 19035415
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
    Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
    Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity.
    Kerekes G; Szekanecz Z; Dér H; Sándor Z; Lakos G; Muszbek L; Csipö I; Sipka S; Seres I; Paragh G; Kappelmayer J; Szomják E; Veres K; Szegedi G; Shoenfeld Y; Soltész P
    J Rheumatol; 2008 Mar; 35(3):398-406. PubMed ID: 18203326
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis.
    Gonzalez-Gay MA; Gonzalez-Juanatey C; Lopez-Diaz MJ; Piñeiro A; Garcia-Porrua C; Miranda-Filloy JA; Ollier WE; Martin J; Llorca J
    Arthritis Rheum; 2007 Feb; 57(1):125-32. PubMed ID: 17266100
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis.
    Hürlimann D; Forster A; Noll G; Enseleit F; Chenevard R; Distler O; Béchir M; Spieker LE; Neidhart M; Michel BA; Gay RE; Lüscher TF; Gay S; Ruschitzka F
    Circulation; 2002 Oct; 106(17):2184-7. PubMed ID: 12390945
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Atherogenesis in rheumatoid arthritis: the "rheumatoid vasculopathy"?
    Fietta P; Delsante G
    Acta Biomed; 2009; 80(3):177-86. PubMed ID: 20578409
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?
    Listing J; Strangfeld A; Kekow J; Schneider M; Kapelle A; Wassenberg S; Zink A
    Arthritis Rheum; 2008 Mar; 58(3):667-77. PubMed ID: 18311816
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vascular endothelial growth factor A and cardiovascular disease in rheumatoid arthritis patients.
    Rodríguez-Rodríguez L; García-Bermúdez M; González-Juanatey C; Vazquez-Rodriguez TR; Miranda-Filloy JA; Fernández-Gutierrez B; Llorca J; Martín J; González-Gay MA
    Tissue Antigens; 2011 Apr; 77(4):291-7. PubMed ID: 21388351
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?
    Askling J; van Vollenhoven RF; Granath F; Raaschou P; Fored CM; Baecklund E; Dackhammar C; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Rantapää-Dahlqvist S; Saxne T; Klareskog L
    Arthritis Rheum; 2009 Nov; 60(11):3180-9. PubMed ID: 19877027
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Correlation between different clinical activity and anti CC-P (anti-cyclic citrullinated peptide antibodies) titres in rheumatoid arthritis treated with three different tumor necrosis factors TNF-alpha blockers].
    Benucci M; Turchini S; Parrochi P; Boccaccini P; Manetti R; Cammelli E; Manfredi M
    Recenti Prog Med; 2006 Mar; 97(3):134-9. PubMed ID: 16700418
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor necrosis factor (TNF) inhibitor therapy for rheumatoid arthritis.
    Segal B; Rhodus NL; Patel K
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Dec; 106(6):778-87. PubMed ID: 18930662
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Rheumatoid arthritis: current status of therapy].
    El Bahri DM; Meddeb N; Sellami S
    Tunis Med; 2007 Jan; 85(1):1-8. PubMed ID: 17424701
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapy Insight: managing cardiovascular risk in patients with rheumatoid arthritis.
    Giles JT; Post W; Blumenthal RS; Bathon JM
    Nat Clin Pract Rheumatol; 2006 Jun; 2(6):320-9. PubMed ID: 16932711
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Review of the protective effects of tumor necrosis factor inhibitors in rheumatoid arthritis].
    Finckh A; Gabay C; Guerne PA
    Rev Med Suisse Romande; 2004 Sep; 124(9):547-50. PubMed ID: 15552748
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Subclinical atherosclerosis and endothelial dysfunction in patients with early rheumatoid arthritis as evidenced by measurement of carotid intima-media thickness and flow-mediated vasodilatation: an observational study.
    Chatterjee Adhikari M; Guin A; Chakraborty S; Sinhamahapatra P; Ghosh A
    Semin Arthritis Rheum; 2012 Apr; 41(5):669-75. PubMed ID: 22035626
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased cardiovascular risk in patients with rheumatoid arthritis: an overview.
    Puttevils D; De Vusser P; Geusens P; Dens J
    Acta Cardiol; 2014 Apr; 69(2):111-8. PubMed ID: 24783461
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiovascular risk in rheumatoid arthritis: pathogenesis, diagnosis, and management.
    Gkaliagkousi E; Gavriilaki E; Doumas M; Petidis K; Aslanidis S; Stella D
    J Clin Rheumatol; 2012 Dec; 18(8):422-30. PubMed ID: 23188207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.